Content area

|
|

Nye antidiabetiske lægemidler og kardiovaskulære komplikationer

Forfatter(e)
Manan Pareek1, 2, 3, Martin Bødtker Mortensen4, 5, Bo Løfgren4, Mette Lundgren Nielsen3, Michael Hecht Olsen2 & Niels Holmark Andersen6 1) Brigham and Women’s Hospital Heart & Vascular Center, Harvard Medical School, Boston, USA 2) Medicinsk Afdeling, Holbæk Sygehus 3) Endokrinologisk Afdeling, Odense Universitetshospital 4) Medicinsk Afdeling, Regionshospitalet Randers 5) Afdeling for Hjertesygdomme, Aarhus Universitetshospital 6) Kardiologisk Afdeling, Aalborg Universitetshospital Ugeskr Læger 2018;180:V07170551
Reference: 
Ugeskr Læger 2018;180:V07170551
Blad nummer: 
Sidetal: 
2-6
Novel antidiabetic drugs and cardiovascular complications
This review summarizes the cardiovascular non-inferiority trials of novel antidiabetic drugs performed since 2008, when regulatory agencies started mandating thorough examination of their cardiovascular safety. So far, eight randomized trials on three different drug classes have been completed. Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists may reduce cardiovascular risk and possibly mortality, while dipeptidyl dipeptidase-4 inhibitors may increase the risk of heart failure. A brief discussion of potential mechanisms and clinical implications is provided.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Camilla Bang | 16/10
1 Kommentar
af Tobias Ramm Eberlein | 15/10
6 kommentarer
af Frank Bang Nissen | 15/10
1 Kommentar
af Peter Hvidbak Revald | 14/10
3 kommentarer
af Arne Mejlhede | 11/10
1 Kommentar
af Sven Refslund Poulsen | 06/10
3 kommentarer